1. Home
  2. ACIU vs PROF Comparison

ACIU vs PROF Comparison

Compare ACIU & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AC Immune SA

ACIU

AC Immune SA

N/A

Current Price

$2.76

Market Cap

247.6M

Sector

Health Care

ML Signal

N/A

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

N/A

Current Price

$5.85

Market Cap

248.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACIU
PROF
Founded
2003
N/A
Country
Switzerland
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.6M
248.8M
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
ACIU
PROF
Price
$2.76
$5.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$8.57
★ $11.14
AVG Volume (30 Days)
★ 146.7K
127.4K
Earning Date
11-03-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.89
EPS
★ N/A
N/A
Revenue
N/A
★ $16,098,000.00
Revenue This Year
$422.39
$64.06
Revenue Next Year
$377.85
$64.17
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 50.73
52 Week Low
$2.10
$4.91
52 Week High
$4.00
$8.95

Technical Indicators

Market Signals
Indicator
ACIU
PROF
Relative Strength Index (RSI) 49.96 40.68
Support Level $2.58 $5.55
Resistance Level $2.68 $6.06
Average True Range (ATR) 0.14 0.25
MACD -0.02 0.02
Stochastic Oscillator 49.81 28.75

Price Performance

Historical Comparison
ACIU
PROF

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: